Sandwich Assay Patents (Class 435/7.94)
  • Patent number: 10705079
    Abstract: Disclosed is a method for preparing a magnetic microsphere for the separation of biological proteins. A magnetic microsphere matrix is treated by formulating and using an appropriate emulsified liquid, and modification of the surface of the magnetic microsphere matrix is realized by emulsion polymerization, thereby obtaining a magnetic microsphere coated with a polyacrylate polymer layer. Said emulsified liquid comprises the following components therein: acyclic acid monoester compounds, acyclic acid glycol compounds, initiators and optionally anionic surface active agents and water. The magnetic microsphere significantly reduces the non-specific adsorption of other proteins, without affecting the joining ability for a specific protein, when used in the separation of biological proteins. A new selection is provided to realize the separation engineering of high protein specificity adsorption.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: July 7, 2020
    Assignee: SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
    Inventors: Wei Rao, Kai Du, Li Zhao
  • Patent number: 10648970
    Abstract: The present invention lies in the field of visualization and quantification of immobilized targets in samples using immunochemical means. In particular, the invention relates to a method and reagents for detection, visualization and quantification of a molecular target in immunostained histological samples using particular compositions of the target specific binding agent. Methods and compositions of the invention are suitable for any assay that uses a target visualization system in histological samples based on detection of the target by the target specific binding agent. The methods and compositions are useful for evaluation of targets that are biomarkers of diseases in medical diagnostic.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: May 12, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Jesper Lohse, Kristian Jensen, Rikke Malene Krusenst Jerna-Hafstrom, Kirsten Damgaard Hoff, Lars Christian Jacobsen
  • Patent number: 10620206
    Abstract: Methods for detecting colorectal cancer in a subject by detection of a galactose-containing 40 kDa molecule in a serum sample from the subject. Methods for quantifying the amount of a galactose-containing molecule in a serum sample are also provided.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: April 14, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert Bresalier, Nachman Mazurek, James C. Byrd
  • Patent number: 10514379
    Abstract: The present invention relates to systems and methods that utilize a combination of immunoassay and magnetic immunoassay techniques to detect an analyte within an extended range of specified concentrations. In particular, a device includes a first immunosensor including an immobilized layer of capture antibodies configured to bind to a first complex of signal antibodies and cardiac troponin such that a second complex of the first complex and the immobilized layer of capture antibodies is localized on or near the first immunosensor. The device further includes a second immunosensor having a magnetic field disposed locally around the second immunosensor. The magnetic field is configured to attract magnetic beads such that a third complex of the first complex and capture antibodies immobilized on the magnetic beads is localized on or near the second immunosensor sensor.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: December 24, 2019
    Assignee: Abbott Point of Care Inc.
    Inventors: Jing Hua Hu, Antti Leo Oskari Virtanen, Eric Edward Potter, James T. K. Smith, Cary James Miller, John Lewis Emerson Campbell, Adam Roger Moss
  • Patent number: 10192030
    Abstract: Provided are biological methods for measuring enzyme activity. The methods include generating reactions, and contacting each reaction generated with a set of internal standards, where each of the internal standards includes a different amount of product. The methods also include generating a standard curve for each of the reactions from the internal standards in each of the reactions.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: January 29, 2019
    Inventors: Juliesta Elaine Sylvester, Stephen Joseph Kron
  • Patent number: 10180426
    Abstract: The present invention lies in the field of visualization and quantification of immobilized targets in samples using immunochemical means. The methods of the invention utilize an immunostaining system allowing visualizing single target units in samples as distinct dots. In particular, the invention relates to methods and reagents for visualization and quantification of molecular targets immunostained in histological samples and use of said method and reagents in medical diagnostic. However, the visualization and quantification methods of the invention are applicable to a variety of targets in different samples and allow precise quantifying both relative and absolute amounts thereof.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: January 15, 2019
    Assignee: DAKO DENMARK A/S
    Inventors: Jesper Lohse, Galina Skladtchikova
  • Patent number: 10035841
    Abstract: This disclosure pertains to isolated antibodies or antigen binding fragments thereof that specifically bind to the 3ABC non-structural protein of Foot-and-Mouth Disease virus (FMDV), wherein the antibodies or antigen binding fragments thereof recognize the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 12. Accordingly, this disclosure also pertains to polypeptides having an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 12. Monoclonal antibody Mab 40C8 is also provided. The current disclosure also pertains to methods of detecting FMDV infection in an animal (including assays differentiating infected animals from vaccinated animals (DIVA)) and kits for performing the detection methods.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 31, 2018
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HOMELAND SECURITY
    Inventors: Alfonso Clavijo, Aida Elizabeth Rieder, Abu Sayed, Mangkey A. Bounpheng, Thomas G. Burrage, Brooke A. Dancho, Sabena Uddowla Blakeney
  • Patent number: 9958442
    Abstract: A sensor comprising an electronic circuit electrically coupled to a type III-V semiconductor material, for example indium arsenide (InAs) and an antibody contacting the type III-V semiconductor material. The sensor produces measurable N changes in the electrical properties of the semiconductor upon antibody-antigen binding events. Electrical properties measurable by the electronic device may include resistivity, capacitance, impedance, and inductance. A method of detecting an antigen using sensors of the invention. A method of detecting a reaction of an analyte to a stimulus using sensors of the invention. Sensor arrays comprising multiple sensors of the invention.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: May 1, 2018
    Assignee: Duke University
    Inventors: R. Michael Angelo, April S. Brown, Scott Wolter, William V. Lampert
  • Patent number: 9844778
    Abstract: A testing module is provided. The testing module includes a carrier, a block member, and a sampling assembly. A flow path connects a storage chamber to a mixing chamber to guide the flow of a fluid. The block member is formed in the flow path to block the fluid from flowing from the storage chamber to the mixing chamber before the connection of the sampling assembly. When the sampling assembly which contains a test sample is connected to the carrier, the fluid mixes with the test sample and flows to the mixing chamber.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: December 19, 2017
    Assignee: LITE-ON TECHNOLOGY CORPORATION
    Inventors: Yi An Shih, Fu Chun Huang, Cheng Chang Lai
  • Patent number: 9777268
    Abstract: The invention relates to a method of immobilising at least one RNA molecule onto a surface of a support comprising: i) providing a first support having a surface on which at least one DNA molecule is immobilised, wherein the DNA molecule encodes an RNA molecule and the encoded RNA molecule comprises a binding molecule; ii) providing a second support having a surface on which at least one binding partner for interacting with the binding molecule is immobilised; iii) arranging the first and second supports such that the surfaces displaying the immobilised molecules are in close proximity and substantially face each other, and contacting the DNA molecule immobilised on the surface of the first support with transcription reagents; and iv) carrying out a transcription reaction to generate the encoded RNA molecule, wherein the RNA molecule is directly immobilised onto the surface of the second support via an interaction between the binding molecule of the RNA molecule and the binding partner on the surface of the s
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITY OF PORTSMOUTH
    Inventor: Anastasia Jane Callaghan
  • Patent number: 9658152
    Abstract: The inventive concepts disclosed herein are generally directed to the use of a hand-held mobile computing device, such a smartphone or tablet, to interpret the results of a medical assay device. By controlling conditions like image placement and illumination and correcting for imperfect illumination, accurate results can be obtained with hand-held mobile computing device.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: May 23, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Chris Thomas Zimmerle, Gary W. Rheinheimer, James Arthur Profitt
  • Patent number: 9618523
    Abstract: Methods include determining in a sample an amount of a first isomeric analyte and a second isomeric analyte. A first measurement value and a second measurement value are determined. The first measurement value represents a total amount of the first isomeric analyte and the second isomeric analyte. The second measurement value represents an amount of the second isomeric analyte only. The second measurement value is subtracted from the first measurement value to obtain a resulting value and the resulting value is equated to an amount of the first isomeric analyte in the sample.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: April 11, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Tie Q. Wei, Izak Bahar
  • Patent number: 9562905
    Abstract: Methods for the detection of, or the risk of, bladder cancer in a patient, comprising assaying for the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein detecting the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: February 7, 2017
    Assignee: RADOX LABORATORIES LIMITED
    Inventors: Mark W. Ruddock, Cherith N. Reid, Kathleen Williamson, John V. Lamont, Stephen P. Fitzgerald
  • Patent number: 9556245
    Abstract: The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. An amino terminal extension is presented, which comprises four genomic exons. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. More specifically, this invention is directed to a CA125 cDNA sequence which can be introduced into animal or human cells to achieve transcription or expression of the cDNA.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: January 31, 2017
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Timothy O'Brien, John Beard, Lowell Underwood
  • Patent number: 9504731
    Abstract: The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: November 29, 2016
    Assignee: National University Corporation Okayama University
    Inventors: Masahiro Nishibori, Shuji Mori, Hidenori Wake, Hideo Takahashi, Keyue Liu, Kiyoshi Teshigawara, Masakiyo Sakaguchi
  • Patent number: 9371382
    Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 21, 2016
    Assignee: Nexus DX, Inc.
    Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
  • Patent number: 9222937
    Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and the use of such measurements for the detection and diagnosis of disease.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: December 29, 2015
    Assignee: Singapore Volition Pte. Limited
    Inventor: Jacob Vincent Micallef
  • Patent number: 9207233
    Abstract: An ELISPOT method for in vitro diagnosis and/or in vitro therapy monitoring of infections and/or infectious diseases comprising incubating eukaryotic cells with an antigen, measuring the number of immunocompetent cells which secrete at least two different cytokines as a reaction to the antigen, and in measuring the immunocompetent cells, visualizing the cells with the aid of at least two different dyes and at least two different filter sets, the filter sets comprising narrowband filters.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: December 8, 2015
    Assignee: Autoimmun Diagnostika GmbH
    Inventor: Volkmar Schollhorn
  • Patent number: 9206242
    Abstract: It is intended to identity a protein involved in a molecular mechanism between Akt and cell motility as well as to elucidate its function and find its application. In the present teachings, for achieving the above object, protein or partial peptide thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID: 2 is utilized in the screening of a compound or a salt thereof that activates or inhibits any of cell motility, cell migration and angiogenesis.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: December 8, 2015
    Assignee: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Masahide Takahashi, Atsushi Enomoto
  • Patent number: 9199234
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9201078
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9146234
    Abstract: A disease detection system which includes an electrophoresis apparatus and a biomarker detector. The apparatus includes: (a) a transport passage; (b) a plurality of separation passages, each of the separation passages having an overlapping portion that overlaps the transport passage; and (c) a different biomarker concentrator in each of the overlapping portions and which concentrates at least one different biomarker from a specimen from an animal introduced into the transport passage. A plurality of the different biomarkers is associated with at least one predetermined disease, such as diabetes, heart disease or cancer. The detector detects the presence of the different biomarkers which were concentrated by the biomarker concentrators and delivered to the biomarker detector via the separation passages. First and second sets of the biomarker concentrators can be associated with respective first and second predetermined diseases and the user can determine which set will be used in each procedure.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: September 29, 2015
    Assignee: PRINCETON BIOCHEMICALS, INC.
    Inventor: Norberto A. Guzman
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150148259
    Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Paul R. Thompson, Kevin L. Bicker, Venkataraman Subramanian
  • Publication number: 20150141332
    Abstract: Methods for managing osteoarthritis, in a human or other mammalian subject, comprising the measurement of certain cytokines and growth factors in a tissue sample of a subject, including one or more of platelet-derived growth factor AB (PDGF-AB), platelet-derived growth factor BB (PDGF-BB), and epidermal growth factor (EGF). Tissue samples may be whole blood, blood fractions, urine, saliva, and synovial fluid. Methods include diagnosing osteoarthritis, and methods for assessing the severity of osteoarthritis, such as in subject that have been diagnosed with osteoarthritis using radiographic or other methods. Methods may also include comparison of measured cytokine levels to a reference level. Methods of managing the clinical progression of osteoarthritis include initiating a clinical action based on the difference between the measured cytokine level and a reference level.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 21, 2015
    Applicant: Biomet Biologics, LLC
    Inventor: Krista Toler
  • Publication number: 20150141322
    Abstract: The present invention provides a therapeutic agent, a treatment method and an inspection method for diseases caused by activation of neutrophils. More specifically, the invention relates to a neutrophil activation regulator which comprising a histidine-rich glycoprotein (HRG) as an active ingredient, and provides a therapeutic agent for diseases caused by neutrophil activation comprising the neutrophil activation regulator, a treatment method for diseases caused by neutrophil activation, and further an inspection method for diseases caused by neutrophil activation. The present invention is based on the neutrophil activation regulator including the HRG as an active ingredient. The present invention extends to the depressant agent for neutrophil-vascular endothelial cell interaction including the HRG of the present invention as an active ingredient, the treatment method for diseases caused by neutrophil activation and/or inflammatory diseases accompanied by neutrophil activation.
    Type: Application
    Filed: May 28, 2013
    Publication date: May 21, 2015
    Applicant: National University Corporation Okayama University
    Inventors: Masahiro Nishibori, Shuji Mori, Hidenori Wake, Hideo Takahashi, Keyue Liu, Kiyoshi Teshigawara, Masakiyo Sakaguchi
  • Publication number: 20150139989
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Application
    Filed: January 5, 2015
    Publication date: May 21, 2015
    Applicants: FUNDACIO PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA VALL D'HEBRON (VHIO), FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • Publication number: 20150141283
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: September 17, 2014
    Publication date: May 21, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jian CHEN, Ellen FILVAROFF, Sherman FONG, Dorothy FRENCH, Audrey GODDARD, Paul J. GODOWSKI, J. Christopher GRIMALDI, Austin L. GURNEY, Kenneth J. HILIAN, Sarah G. HYMOWITZ, Hanzhong LI, Melissa A. STAROVASNIK, Daniel TUMAS, Menno VAN LOOKEREN, Richard VANDLEN, Colin K. WATANABE, P. Mickey WILLIAMS, William I. WOOD, Daniel G. YANSURA, James PAN
  • Publication number: 20150140582
    Abstract: The invention concerns a test element for carrying out an immunological sandwich test for determining an analyte from a liquid sample containing a reagent zone or conjugate zone which contains a conjugate of an analyte binding partner and a label which can be detected directly or indirectly by visual, optical or electrochemical means (e.g. an enzyme, fluorescent or direct label etc.) wherein said conjugate can be dissolved by the liquid sample, a detection zone which contains a permanently immobilized (i.e. which cannot be detached by the liquid sample) binding partner for the analyte or for complexes containing the analyte; and a control zone which contains a permanently immobilized binding partner for the conjugate of analyte binding partner and label characterized in that the control zone additionally contains one or more permanently immobilized binding partner(s) for the analyte or for complexes containing the analyte.
    Type: Application
    Filed: December 29, 2014
    Publication date: May 21, 2015
    Inventor: Juergen Klepp
  • Patent number: 9034591
    Abstract: The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 19, 2015
    Assignee: HYTEST LTD.
    Inventors: Natalia N. Tamm, Alexey G. Katrukha, Vladimir L. Filatov, Olga V. Kolosova
  • Patent number: 9034592
    Abstract: The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: May 19, 2015
    Assignee: HYTEST LTD.
    Inventors: Natalia N. Tamm, Alexey G. Katrukha, Vladimir L. Filatov, Olga V. Kolosova
  • Publication number: 20150133337
    Abstract: Devices, systems, and methods for detecting molecules of interest within a collected sample are described herein. In certain embodiments, self-contained sample analysis systems are disclosed, which include a reusable reader component, a disposable cartridge component, and a disposable sample collection component. In some embodiments, the reader component communicates with a remote computing device for the digital transmission of test protocols and test results. In various disclosed embodiments, the systems, components, and methods are configured to identify the presence, absence, and/or quantity of particular nucleic acids, proteins, or other analytes of interest, for example, in order to test for the presence of one or more pathogens or contaminants in a sample.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventors: Ayub Khattak, Clinton Sever
  • Publication number: 20150133378
    Abstract: A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the kidney transplant recipient; measuring the level of clusterin in the urine sample; comparing the level of clusterin in the patient sample to the level of clusterin in a control sample from the urine of a non-fibrotic kidney transplant recipient; diagnosing a kidney transplant recipient with a clusterin level that is significantly higher than the clusterin level in the control as being at an increased risk of developing interstitial fibrosis or tubular atrophy.
    Type: Application
    Filed: April 17, 2013
    Publication date: May 14, 2015
    Inventors: Barbara Murphy, Philip J. O'Connell
  • Publication number: 20150132781
    Abstract: Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease.
    Type: Application
    Filed: September 5, 2014
    Publication date: May 14, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Dahl, Gregor Jordan, Roland Staack
  • Publication number: 20150132777
    Abstract: The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment. The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Sakon NORIKI
  • Publication number: 20150132782
    Abstract: Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.
    Type: Application
    Filed: December 22, 2014
    Publication date: May 14, 2015
    Inventors: Hiroyuki Aburatani, Yutaka Midorikawa, Kiyotaka Nakano, Iwao Ohizumi, Yukio Ito, Susumu Tokita
  • Publication number: 20150132319
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
    Type: Application
    Filed: March 6, 2013
    Publication date: May 14, 2015
    Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
  • Publication number: 20150132757
    Abstract: Disclosed herein is a method of detecting and identifying antigens that are shed into human bodily fluids during infection. The disclosed method allows circulating antigens associated with a particular infection to be detected within minutes or hours from testing as compared to days required with the current methods. Methods of identifying diagnostic indicators/targets for a given condition or disease are disclosed which include immunizing a verterinary subject with biological fluids obtained from a human infected with particular antigens to identify diagnostic targets for immunoassay. Also disclosed are methods of diagnosing and monitoring a B. pseudomallei-associated condition, such as melioidosis. Point-of-care immunoassays are also provided that can be used to diagnose or monitor the efficacy of a B. pseudomallei-associated condition treatment. These immunoassays can also be used for rapid diagnosis of infection produced by B. pseudomallei, such as meliodosis.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 14, 2015
    Applicant: The Board of Regents of the Nevada System of Higher Education, on Behalf of the Univ. of Nevada
    Inventors: David P. AuCoin, Thomas R. Kozel, Claire Smalley
  • Patent number: 9029093
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays configured to detect a kidney injury marker as diagnostic and prognostic biomarkers in renal injuries.
    Type: Grant
    Filed: February 26, 2011
    Date of Patent: May 12, 2015
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Publication number: 20150125886
    Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection.
    Type: Application
    Filed: June 3, 2013
    Publication date: May 7, 2015
    Applicant: Biolncept, LLC
    Inventor: Eytan R. BARNEA
  • Publication number: 20150126401
    Abstract: The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 7, 2015
    Inventors: Johann Karl, Norbert Wild, Ursula Garczarek
  • Publication number: 20150126394
    Abstract: Methods for diagnosing cancer in a subject are disclosed. The method includes detecting the level of expression of one or more cancer markers in a biological sample obtained from the subject; and comparing the level of expression of the one or more cancer markers in the biological sample to a normal level of expression of the one or more cancer markers. The one or more cancer markers comprises CXCL13 or CXCR5 or both CXCL13 and CXCR5. Also disclosed is a kit for detecting cancer or monitoring cancer progression.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 7, 2015
    Inventors: James W. LILLARD, JR., Rajesh Singh, Shailesh Singh
  • Publication number: 20150118156
    Abstract: Provided herein are antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 30, 2015
    Inventors: Bernhard Mueller, Lili Huang, Philip D. Bardwell, Yuliya Kutskova, John Memmott
  • Publication number: 20150114310
    Abstract: The present invention provides compositions and methods for detection schemes for ascertaining pregnancy status of an animal. The compositions and methods employ interferon-tau (IFNT) and/or antibodies specific for IFNT. Methods of the present invention detect the presence of IFNT in samples obtained from animals as an early indicator of pregnancy. Methods are provided to identify non-pregnant animals so that management decisions regarding rebreeding can be made earlier compared to existing approaches.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Thomas R. Hansen, Jessica Prenni, Torrance M. Nett, Kevin McSweeney, Jared Romero
  • Publication number: 20150118698
    Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
    Type: Application
    Filed: May 4, 2012
    Publication date: April 30, 2015
    Applicant: Nordic Biociences A/S
    Inventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
  • Publication number: 20150118699
    Abstract: Markers useful in diagnosing disseminated intravascular coagulation (DIC) or infectious DIC are provided. In a method for detecting DIC of the present invention, sCD14-ST in a sample is measured. In a method of detecting infectious DIC of the present invention, sCD14-ST and a coagulation-related marker in a sample are measured.
    Type: Application
    Filed: April 26, 2013
    Publication date: April 30, 2015
    Inventor: Hiroyasu Ishikura
  • Publication number: 20150119271
    Abstract: The present invention relates to a method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising: determining the level of at least one biomarker selected from the group consisting of proET-1, pro ADM, proANP, proBNP, proAVP and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient, correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Inventors: Joachim Struck, Olle Melander, Artur Fedorowski
  • Patent number: 9017958
    Abstract: The invention provides a method for detecting heparin-induced antibodies comprising a) binding a PF4-heparin antigen to a solid surface; b) incubating the bound PF4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of Ig, IgG, IgA, and IgM.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 28, 2015
    Assignee: BloodCenter Research Foundation, Inc.
    Inventor: Brian R. Curtis
  • Patent number: 9017959
    Abstract: Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the ?-E chain and ? chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: April 28, 2015
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Wataru Kikuchi, Momoe Sato, Kenta Noda, Iwao Kiyokawa, Toshihide Miura, Ryo Kojima, Fumio Nomura, Kazuyuki Sogawa
  • Publication number: 20150111758
    Abstract: The present invention relates to compositions, kits, and methods for providing a prognosis and/or determining a treatment course of action in a subject diagnosed with breast cancer. In particular, the present invention relates to gene expression signatures useful in the prognosis, diagnosis, and treatment of breast cancer.
    Type: Application
    Filed: March 6, 2013
    Publication date: April 23, 2015
    Inventors: Therese Sorlie, Arnoldo Frigessi, Anne-Lise Borresen-Dale, Simen Myhre, Hayat Mohammed, Jens Overgaard, Jan Alsner, Trine Tramm